USA flag logo/image

An Official Website of the United States Government

PFK-015: An inhibitor of PFKFB3 to treat Glioblastomas

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43CA165300
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA11-096
Small Business Information
ADVANCED CANCER THERAPEUTICS, LLC
429 W. MUHAMMAD ALI BLVD. SUITE 600 LOUISVILLE, KY 40202-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: PFK-015: An inhibitor of PFKFB3 to treat Glioblastomas
Agency: HHS
Contract: 1R43CA165300-01A1
Award Amount: $157,920.00
 

Abstract:

DESCRIPTION (provided by applicant): Amongst the different cancer types afflicting the US population, glioblastoma multiforme (GBM) is a dreadful disease with an overall average survival of 10 months. With about 8,000 new cases per year, representing onlyabout 2% of new cancer patients, this disease benefits from an Orphan drug designation. Also, new therapies are needed to prolong patients' survival. New therapies based on novel mechanisms of action or inhibiting new biological pathways are required to improve cancer patients' survival. The Warburg effect, the higher rate of glucose metabolism of cancer cells was identified as a potential cancer target many decades ago. PFKFB3 is a key enzyme involved in the glycolytic pathway and is also required for tumor growth in animal models. Thus, inhibiting PFKFB3 may prove to be a useful strategy for the development of novel anti-neoplastic agents targeting the energy needs of cancer cells. Advanced Cancer Therapeutics (ACT), in collaboration with Jason Chesney,MD, PhD, at the Brown Cancer Center, University of Louisville, KY, who validated preclinically PFKFB3 as a potential cancer target, proposes to complete the characterization of PFK-015 in GBM preclinical models. PFK-015, is a potent inhibitor of PFKFB3, and preliminary results in a U87GM xenograft model have shown that PFK-015 has comparable activity to Temozolomide and that PFK-015 crosses the blood brain barrier. The work proposed in this application encompasses 1) completion of the in vitro characterization of PFK-015 by screening its activity in 7 glioblastoma cell lines and synergies with Temozolomide; 2) characterization of the PK profile of PFK-015 in mice including determining brain and plasma levels; and 3) tumor growth inhibition studies in several orthotopic models. Positive results in the studies described above would warrant additional preclinical studies (i.e. efficacy, toxicology) in order to determine if PFK-015 should undergo IND enabling testing to initiate a Phase I study in GBM cancer patients. PUBLIC HEALTH RELEVANCE: Amongst the different cancer types afflicting the US population, glioblastoma multiforme (GBM) is a dreadful disease with an overall average survival of 10 months. While it constitutes only approximately 2% of allnew cancer patients, with about 8,000 new cases per year, new therapies are clearly needed for this disease that benefits from an Orphan drug designation. This application proposes to investigate the use of a novel class of anticancer agents in GBM preclinical models. PFKFB3 is a protein involved in the glycolytic pathway and commonly over expressed in many cancers (pancreatic, lung, breast, brain, ovarian...) including glioblastomas. Preliminary results obtained with PFK-015, a potent inhibitor of PFKFB3,in a glioblastoma xenograft model have shown that it has tumor growth inhibition activity comparable to that of Temozolomide, the drug currently used as first line therapy for the treatment of glioblastoma multiforme. Furthermore, PFK-015 inhibits glucoseuptake by tumors as shown by PET imaging and crosses the blood brain barrier. In this application, additional PK and in vitro experiments will be done to further understand the properties of PFK-015 and determine if it has synergy with Temozolomide. Efficacy studies in several glioblastoma models will be performed, including combinations studies. A therapeutic agent based on a novel mechanism of action that would have activity as a single agent and synergies with the compound currently used as first linetherapy would be extremely valuable and cancer patients would tremendously benefit from such an opportunity.

Principal Investigator:

Gilles H. Tapolsky
502-589-6404
gtapolsky@advancedact.com

Business Contact:

Robert Riggs
502-589-6404
rriggs@advancedact.com
Small Business Information at Submission:

ADVANCED CANCER THERAPEUTICS, LLC
429 W. MUHAMMAD ALI BLVD. SUITE 600 LOUISVILLE, KY 40202-

EIN/Tax ID: 120829553
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No